{"id":"course-a2-vin","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Alopecia"},{"rate":null,"effect":"Peripheral neuropathy"},{"rate":null,"effect":"Cardiotoxicity"},{"rate":null,"effect":"Mucositis"}]},"_chembl":{"chemblId":"CHEMBL610864","moleculeType":"Small molecule","molecularWeight":"1584.08"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This regimen combines doxorubicin (a topoisomerase II inhibitor that intercalates DNA and prevents replication) with vincristine (a microtubule inhibitor that arrests cells in metaphase). The combination is designed to provide synergistic cytotoxic effects against rapidly dividing cancer cells in children. Course A2 typically refers to a specific protocol iteration used in pediatric oncology treatment schedules.","oneSentence":"Course A2 + Vin is a combination chemotherapy regimen that uses doxorubicin and vincristine to inhibit cancer cell division and induce apoptosis in pediatric malignancies.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:07:45.761Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Pediatric acute lymphoblastic leukemia (ALL)"},{"name":"Pediatric lymphomas"}]},"trialDetails":[{"nctId":"NCT04881838","phase":"PHASE3","title":"CCCG-ALCL-2020 for Chinese Children and Adolescents With Newly Diagnosed High-risk ALCL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Cancer Group, China","startDate":"2021-03-01","conditions":"Pediatric Anaplastic Large Cell Lymphoma","enrollment":172}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Course A2 + Vin","genericName":"Course A2 + Vin","companyName":"Children's Cancer Group, China","companyId":"children-s-cancer-group-china","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Course A2 + Vin is a combination chemotherapy regimen that uses doxorubicin and vincristine to inhibit cancer cell division and induce apoptosis in pediatric malignancies. Used for Pediatric acute lymphoblastic leukemia (ALL), Pediatric lymphomas.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}